Table.
Descriptions of 134 included reviews from 2010 to 2022
| Reviews, n (%) | ||
|---|---|---|
| Population data* | ||
| Targeted individuals | ||
| Patients | 128 (95·5%) | |
| Family | 18 (13·4%) | |
| Health-care personnel | 5 (3·7%) | |
| Cancer types | ||
| Brain | 1 (0·7%) | |
| Breast | 17 (12·7%) | |
| Colorectal | 5 (3·7%) | |
| Gynecological | 7 (5·2%) | |
| Haematological | 4 (3·0%) | |
| Lung | 3 (2·2%) | |
| Prostate | 4 (3·0%) | |
| Skin | 6 (4·5%) | |
| Multiple or not specified | 95 (70·9%) | |
| Cancer care continuum | ||
| Prevention | 5 (3·7%) | |
| Screening or diagnosis | 12 (9·0%) | |
| Treatment or symptom management | 48 (35·8%) | |
| Survivorship | 29 (21·6%) | |
| End-of-life or bereavement | 2 (1·5%) | |
| Multiple or not specified | 56 (41·8%) | |
| Intervention data† | ||
| Telehealth components | ||
| Synchronous telehealth | 78 (58·2%) | |
| Text messaging or short messaging service | 37 (27·6%) | |
| Email or secure messaging | 39 (29·1%) | |
| eHealth | 87 (64·9%) | |
| Mobile application | 78 (58·2%) | |
| Types of intervention or care | ||
| Health behaviour change | 24 (17·9%) | |
| Psychosocial support or distress management | 18 (13·4%) | |
| Disease detection or management | 14 (10·4%) | |
| Medical decision making | 2 (1·5%) | |
| Multiple or not specified | 73 (54·5%) | |
| Provider involvement | ||
| Health-care professional | 9 (6·7%) | |
| Fully automated or self-guided | 1 (0·7%) | |
| Multiple or not specified | 124 (92·5%) | |
| Review design data | ||
| Meta-analysis | ||
| Yes | 29 (21·6%) | |
| No | 105 (78·4%) | |
| Comparator (if required) | ||
| Usual care | 11 (8·2%) | |
| In-person | 2 (1·5%) | |
| Any | 18 (13·4%) | |
| Other telehealth modality | 0 (0%) | |
| None required | 103 (76·9%) | |
| Quality or bias assessment | ||
| Yes | 90 (67·2%) | |
| No | 44 (32·8%) | |
| Implementation outcome data (Proctor et al. classification)† | ||
| None | 83 (61·9%) | |
| Acceptability | 36 (26·9%) | |
| Adoption | 8 (6·0%) | |
| Appropriateness | 6 (4·5%) | |
| Feasibility | 32 (23·9%) | |
| Fidelity | 29 (21·6%) | |
| Cost | 8 (6·0%) | |
The median number of studies included per review was 16 with a range from 0–121. Albino de Queiroz and colleagues55 included two reviews within the single publication (N1=121 and N2=15). Each sample was included separately for the computation of these statistics.
*
Reviews might be reflected in more than one category (eg, can include interventions for both patients and family members, or report more than one kind of implementation outcome; except for multiple or not specified, or none).